EEDVD-682 is under clinical development by ImmunityBio and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase II drugs for Kidney Cancer (Renal Cell Cancer) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EEDVD-682’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EEDVD-682 overview
EEDVD-682 is under development for treatment of pancreatic ductal carcinoma (PDAC), solid tumors including bladder cancer, colorectal cancer, head and neck cancer, kidney cancer, melanoma, non-small cell lung cancer (NSCLC). The drug candidate is administered intravenously. It consists of EDV nanocells filled with a payload called PNU-159682 (PNU-682). These payload-packaged EDVs are coated with a antibody which targets epidermal growth factor receptor (EGFR). It is based on EnGeneIC s bacterially-derived EDV nanocell platform.
ImmunityBio overview
ImmunityBio, a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company developing therapies for therapies for cancer and infectious diseases. The company product pipeline includes anktiva + BCG, anktiva + keytruda (pembrolizumab), aldox + anktiva + PD-L1 t-hank, anktiva + tri-ad5 vaccines, anktiva + bevacizumab + PD-L1 t-hank, anktiva + IBRX-042 vaccination, anktiva + M-ceNK and anktiva + CD19 t-haNK. ImmunityBio pipeline candidates treat bladder cancer, lung cancer, lynch syndrome, pancreatic cancer, glioblastoma, HPV, advanced Solid tumors, non-hodgkin lymphoma and HIV. The company operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of EEDVD-682’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.